Hospital
North Broward Hospital District
North Broward Hospital District was paid $4.45M by Medicaid between Jan 2018 and Dec 2024, across 121 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoNORTH BROWARD HOSPITAL DISTRICT
FORT LAUDERDALE, FL 33308
FORT LAUDERDALE, FL 33308
33aNPI1265460232assigned 06/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.45M
24GClaims254,706
24DCodes billed121
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#86 of 163
Median peer was paid$4.77M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BERT, ALISA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,279 | $290K | |
| 2019 | 51,756 | $438K | |
| 2020 | 41,694 | $395K | |
| 2021 | 55,172 | $841K | |
| 2022 | 52,137 | $1.31M | |
| 2023 | 26,092 | $825K | |
| 2024incomplete | 9,576 | $359K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 12,844 | 11,177 | $951K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 13,940 | 11,523 | $941K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 7,008 | 5,662 | $449K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.3% | 1,711 | 1,482 | $280K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.5% | 2,872 | 2,317 | $244K |
| G0378 | Hospital observation service, per hour | 5.1% | 5,960 | 3,112 | $228K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.1% | 3,769 | 3,182 | $183K |
| 36415 | Collection of venous blood by venipuncture | 3.2% | 18,826 | 11,983 | $144K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 2,162 | 1,955 | $140K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 947 | 779 | $117K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 3,605 | 2,741 | $89K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 7,391 | 6,190 | $78K |
109 more codes
| 80053 | Comprehensive metabolic panel | 1.4% | 17,335 | $61K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,905 | $52K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,025 | $38K |
| 87631 | <1% | 378 | $37K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,858 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,412 | $23K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,518 | $20K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 313 | $19K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,725 | $19K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,819 | $19K |
| 87070 | <1% | 1,148 | $19K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 486 | $18K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,568 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 591 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,164 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,565 | $13K |
| 81001 | <1% | 8,042 | $11K | |
| 87486 | <1% | 347 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,453 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 441 | $11K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 381 | $10K |
| 83735 | <1% | 7,274 | $8K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,111 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,234 | $8K |
| 81025 | <1% | 2,024 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,918 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,512 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,015 | $6K |
| 81003 | <1% | 1,334 | $6K | |
| 87077 | <1% | 646 | $6K | |
| 84484 | <1% | 4,115 | $5K | |
| 85610 | <1% | 4,265 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,720 | $5K |
| 85730 | <1% | 3,960 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 694 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,828 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 389 | $4K |
| 83690 | <1% | 3,418 | $3K | |
| 87186 | <1% | 1,168 | $3K | |
| 82550 | <1% | 3,135 | $3K | |
| 87210 | <1% | 152 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 34 | $2K |
| 73630 | <1% | 154 | $2K | |
| 83880 | <1% | 912 | $2K | |
| 84703 | <1% | 3,630 | $2K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,969 | $2K |
| 87040 | <1% | 1,467 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,028 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,037 | $1K |
| 83605 | <1% | 1,508 | $1K | |
| 86850 | <1% | 864 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 325 | $1K |
| 84702 | <1% | 919 | $916.93 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 316 | $809.12 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 545 | $772.00 |
| 76830 | Ultrasound, transvaginal | <1% | 68 | $629.47 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 19 | $604.36 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $536.71 |
| 73030 | <1% | 115 | $534.33 | |
| 93971 | <1% | 84 | $506.67 | |
| 85379 | <1% | 319 | $476.01 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 28 | $444.89 |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 15 | $422.54 |
| 87581 | <1% | 347 | $412.39 | |
| A9270 | Non-covered item or service | <1% | 1,430 | $382.55 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 348 | $367.33 |
| 87088 | <1% | 553 | $325.52 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 494 | $314.06 |
| 80329 | <1% | 74 | $281.18 | |
| 87430 | <1% | 715 | $270.12 | |
| 86900 | <1% | 1,039 | $265.50 | |
| 74022 | <1% | 86 | $158.89 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 73 | $154.08 |
| 80320 | <1% | 103 | $151.60 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,456 | $147.68 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 447 | $128.81 |
| 87205 | <1% | 22 | $112.82 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 805 | $102.41 |
| 86901 | <1% | 1,039 | $100.32 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 124 | $100.00 |
| 73564 | <1% | 17 | $51.66 | |
| 80061 | Lipid panel | <1% | 27 | $44.01 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 634 | $40.00 |
| J3490 | Unclassified drugs | <1% | 338 | $34.23 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 147 | $31.14 |
| 84100 | <1% | 85 | $23.78 | |
| 86140 | <1% | 133 | $20.77 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 248 | $2.66 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 109 | $2.58 |
| 84439 | <1% | 20 | $2.57 | |
| 84132 | 0% | 93 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 215 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 106 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 61 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 49 | $0.00 |
| 96376 | 0% | 67 | $0.00 | |
| 85651 | 0% | 17 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 90 | $0.00 |
| 00731 | 0% | 14 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 44 | $0.00 |
| 88312 | 0% | 12 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 73 | $0.00 |
| 74018 | 0% | 12 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 65 | $0.00 |
| 72110 | 0% | 32 | $0.00 | |
| 88313 | 0% | 12 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 13 | $0.00 |
| 73130 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBERT, ALISA (INTERIM CFO)
Parent organizationNORTH BROWARD HOSPITAL DISTRICT
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.